{"transactions":[{"id":1049203,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares with a nominal value of GBP0.001 per share","published_at":"2025-09-03T17:00:21.000Z","date":"2025-09-02","kind":"sale","planned":false,"acquired":false,"shares":96000,"price":0.0099,"value":950.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares whose sale is reported on this line are represented by American Depositary Shares (\"ADS\") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The 96,000 ordinary shares reported in Column 4 are represented by 16,000 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 of $0.0099 per ordinary share is derived from the sale price of $0.0594 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0594. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The Reporting Person does not hold any ordinary shares in the form of ADSs following this transaction. However, the Reporting Person holds nominal cost options and other options covering an aggregate of 11,140,760 ordinary shares of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-087085","document":"tm2525128d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465925087085/tm2525128d1_4seq1.xml","form_type":"4"}},{"id":1677555,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T17:01:14.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":565416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028."}],"balance_after":565416,"derivative":{"exercise_price":0.0013,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":565416},"source":{"system":"sec-edgar","filing":"0001104659-24-004524","document":"tm243270-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465924004524/tm243270-7_4seq1.xml","form_type":"4"}},{"id":1677554,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T17:01:14.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":2544432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028."}],"balance_after":2544432,"derivative":{"exercise_price":0.14,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":2544432},"source":{"system":"sec-edgar","filing":"0001104659-24-004524","document":"tm243270-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465924004524/tm243270-7_4seq1.xml","form_type":"4"}},{"id":2053535,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-17T21:04:05.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":193728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":193728,"derivative":{"exercise_price":0.0012,"exercise_date":"2024-01-17","expiration_date":"2033-01-17","underlying":"Ordinary Shares","underlying_shares":193728},"source":{"system":"sec-edgar","filing":"0001104659-23-004372","document":"tm231655-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465923004372/tm231655-12_4seq1.xml","form_type":"4"}},{"id":2053534,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-17T21:04:05.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":314256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027."}],"balance_after":314256,"derivative":{"exercise_price":0.0012,"expiration_date":"2033-01-17","underlying":"Ordinary Shares","underlying_shares":314256},"source":{"system":"sec-edgar","filing":"0001104659-23-004372","document":"tm231655-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465923004372/tm231655-12_4seq1.xml","form_type":"4"}},{"id":2053533,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-17T21:04:05.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":1407072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.26 based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027."}],"balance_after":1407072,"derivative":{"exercise_price":0.31,"expiration_date":"2033-01-17","underlying":"Ordinary Shares","underlying_shares":1407072},"source":{"system":"sec-edgar","filing":"0001104659-23-004372","document":"tm231655-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465923004372/tm231655-12_4seq1.xml","form_type":"4"}},{"id":2259503,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares with a nominal value of GBP0.001 per share","published_at":"2022-05-23T21:00:33.000Z","date":"2022-05-20","kind":"purchase","acquired":true,"shares":39000,"price":0.2904,"value":11325.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares (\"ADS\") and are held in the form of ADSs by Gavin Wood. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc."},{"field":"shares","element":"transactionShares","label":"F2","text":"The 39,000 ordinary shares reported in Column 4 are represented by 6,500 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 of $0.2904 per ordinary share is derived from the purchase price paid on May 20, 2022 of $1.7423 per ADS divided by six."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The 96,000 ordinary shares reported in Column 5 include 57,000 ordinary shares represented by 9,500 ADSs owned by Mr. Wood prior to the purchase reported in Column 4. These shares are held in the form of ADSs by Mr. Wood."}],"balance_after":96000,"source":{"system":"sec-edgar","filing":"0001104659-22-064008","document":"tm2216620-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465922064008/tm2216620-1_4seq1.xml","form_type":"4"}},{"id":2435678,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-01-13T21:03:03.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":314256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026."}],"balance_after":314256,"derivative":{"exercise_price":0.0014,"expiration_date":"2032-01-12","underlying":"Ordinary Shares","underlying_shares":314256},"source":{"system":"sec-edgar","filing":"0001104659-22-004154","document":"tm221700-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465922004154/tm221700-7_4seq1.xml","form_type":"4"}},{"id":2435677,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-01-13T21:03:03.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":1407072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.44 based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each\nmonth from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026."}],"balance_after":1407072,"derivative":{"exercise_price":0.6,"expiration_date":"2032-01-12","underlying":"Ordinary Shares","underlying_shares":1407072},"source":{"system":"sec-edgar","filing":"0001104659-22-004154","document":"tm221700-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465922004154/tm221700-7_4seq1.xml","form_type":"4"}},{"id":2910490,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2021-01-11T21:03:11.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":242712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.358422 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on the eleventh of each January from January 11, 2023 through January 11, 2025."}],"balance_after":242712,"derivative":{"exercise_price":0.0014,"expiration_date":"2031-01-11","underlying":"Ordinary Shares","underlying_shares":242712},"source":{"system":"sec-edgar","filing":"0001104659-21-003134","document":"tm212800-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465921003134/tm212800-6_4seq1.xml","form_type":"4"}},{"id":2910489,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2021-01-11T21:03:11.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":1086816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.76 based on an exchange rate of U.S.$ 1.358422 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025."}],"balance_after":1086816,"derivative":{"exercise_price":1.03,"expiration_date":"2031-01-11","underlying":"Ordinary Shares","underlying_shares":1086816},"source":{"system":"sec-edgar","filing":"0001104659-21-003134","document":"tm212800-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465921003134/tm212800-6_4seq1.xml","form_type":"4"}},{"id":2941910,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares with a nominal value of GBP0.001 per share","published_at":"2020-12-16T21:00:59.000Z","date":"2020-12-14","kind":"purchase","acquired":true,"shares":24000,"price":0.6896,"value":16550.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares (\"ADS\") and are held in the form of ADSs by Gavin Wood. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc."},{"field":"shares","element":"transactionShares","label":"F2","text":"The 24,000 ordinary shares reported in Column 4 are represented by 4,000 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 of $0.6896 per ordinary share is derived from the purchase price paid on December 14, 2020 of $4.1375 per ADS divided by six."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The 57,000 ordinary shares reported in Column 5 include 33,000 ordinary shares represented by 5,500 ADSs owned by Mr. Wood prior to the purchase reported in Column 4. These shares are held in the form of ADSs by Mr. Wood."}],"balance_after":57000,"source":{"system":"sec-edgar","filing":"0001104659-20-136481","document":"tm2038497-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465920136481/tm2038497-2_4seq1.xml","form_type":"4"}},{"id":3096314,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares with a nominal value of GBP0.001 per share","published_at":"2020-06-30T21:01:10.000Z","date":"2020-06-29","kind":"purchase","acquired":true,"shares":33000,"price":1.62,"value":53460.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares (\"ADS\") and are held in the form of ADSs by Gavin Wood. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc."},{"field":"shares","element":"transactionShares","label":"F2","text":"The 33,000 ordinary shares reported in Column 4 are represented by 5,500 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 of $1.62 per ordinary share is derived from the purchase price paid on June 29, 2020 of $9.7497 per ADS divided by six."}],"balance_after":33000,"source":{"system":"sec-edgar","filing":"0001104659-20-079248","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465920079248/a4.xml","form_type":"4"}},{"id":3188699,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2020-04-01T19:06:11.000Z","date":"2020-04-01","kind":"grant","acquired":true,"shares":565000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.245481 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 141,250 Ordinary Shares on April 1, 2021 and will be exercisable as to the remainder in annual installments of 141,250 Ordinary Shares on the first of each April from April 1, 2022 through April 1, 2024."}],"balance_after":565000,"derivative":{"exercise_price":0.0012,"expiration_date":"2030-04-01","underlying":"Ordinary Shares","underlying_shares":565000},"source":{"system":"sec-edgar","filing":"0001104659-20-042012","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465920042012/a4.xml","form_type":"4"}},{"id":3188698,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":75820,"kind":"person","name":"Wood Gavin","position":1,"cik":"0001577539","reported_name":"Wood Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2020-04-01T19:06:11.000Z","date":"2020-04-01","kind":"grant","acquired":true,"shares":2500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.36 based on an exchange rate of U.S.$1.245481 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 625,000 Ordinary Shares on April 1, 2021 and will be exercisable as to the remainder in monthly installments of 52,080 Ordinary Shares on the first of each month from May 1, 2021 through March 1, 2024 and 52,200 Ordinary Shares on April 1, 2024."}],"balance_after":2500000,"derivative":{"exercise_price":0.45,"expiration_date":"2030-04-01","underlying":"Ordinary Shares","underlying_shares":2500000},"source":{"system":"sec-edgar","filing":"0001104659-20-042012","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577539/000110465920042012/a4.xml","form_type":"4"}}]}